Foamy Virus Budding and Release by Hütter, Sylvia et al.
Viruses 2013, 5, 1075-1098; doi:10.3390/v5041075 
 
viruses 
ISSN 1999-4915 
www.mdpi.com/journal/viruses 
Review 
Foamy Virus Budding and Release 
Sylvia Hütter 
1,2,†
, Irena Zurnic 
1,2,†
 and Dirk Lindemann 
1,2,
* 
1
 Institute of Virology, Medical Faculty "Carl Gustav Carus", Technische Universität Dresden, 
Fetscherstr. 74, Dresden 01307, Germany; E-Mails: Sylvia.huetter@mailbox.tu-dresden.de (S.H); 
irena.zurnic@mailbox.tu-dresden.de (I.Z.) 
2 
DFG-Center for Regenerative Therapies Dresden (CRTD)—Cluster of Excellence,  
Technische Universität Dresden, Fetscherstr. 105, Dresden 01307, Germany  
†
 These authors contributed equally to this work. 
* Author to whom correspondence should be addressed; E-Mail: dirk.lindemann@tu-dresden.de;  
Tel.: +49-351458-6210; Fax: +49-351-458-6310. 
Received: 4 February 2013; in revised form: 25 March 2013 / Accepted: 29 March 2013 /  
Published: 10 April 2013 
 
Abstract: Like all other viruses, a successful egress of functional particles from infected 
cells is a prerequisite for foamy virus (FV) spread within the host. The budding process of 
FVs involves steps, which are shared by other retroviruses, such as interaction of the capsid 
protein with components of cellular vacuolar protein sorting (Vps) machinery via late 
domains identified in some FV capsid proteins. Additionally, there are features of the FV 
budding strategy quite unique to the spumaretroviruses. This includes secretion of  
non-infectious subviral particles and a strict dependence on capsid-glycoprotein interaction 
for release of infectious virions from the cells. Virus-like particle release is not possible 
since FV capsid proteins lack a membrane-targeting signal. It is noteworthy that in 
experimental systems, the important capsid-glycoprotein interaction could be bypassed by 
fusing heterologous membrane-targeting signals to the capsid protein, thus enabling 
glycoprotein-independent egress. Aside from that, other systems have been developed to 
enable envelopment of FV capsids by heterologous Env proteins. In this review article, we 
will summarize the current knowledge on FV budding, the viral components and their 
domains involved as well as alternative and artificial ways to promote budding of FV 
particle structures, a feature important for alteration of target tissue tropism of FV-based 
gene transfer systems.  
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1. Introduction 
The step crucial for virus spread within the infected host is the egress of virus particles from the 
initial and any successively infected cell. Though there are variations of this process as virus spread 
both by release and subsequent infection of other cells or by direct transfer between neighboring cells 
are observed. During evolution, numerous virus genera have devised a variety of ways to ensure proper 
particle egress from the host cell, thus enabling infection of naïve cells and production of new  
virus progeny.  
The release of enveloped viruses, including retroviruses, from the cell surface, is a highly 
coordinated process, usually aided by a number of cellular factors [1]. Budding of viruses can occur 
simultaneously with virus assembly or start only after fully assembled, but immature, viral cores have 
formed in the cytoplasm. The subcellular location of virus budding also varies among virus genera and 
for specific virus species sometimes also in dependence of the target tissue type infected [2]. It can 
either take place at the plasma membrane or at an intracellular compartment. In the latter case, 
however, it is not yet fully clarified how the virus-containing vesicles exit the cell, the most often 
proposed mechanism being exocytosis. 
In general, retroviruses follow two budding pathways that are also represented in Figure 1:  
1. Particle assembly occurs at the plasma membrane, in regions enriched in envelope glycoprotein. 
Oligomerization of capsid protein leads to formation of the particle, its growth and bending of the 
plasma membrane, after which the assembled virion pinches off. This is characteristic of C-type 
retroviruses, such as human immunodeficiency virus type 1 (HIV-1) [3] or murine leukemia virus 
(MuLV) [4]. As mentioned, here capsid assembly and virion budding occur simultaneously. 
However, importantly, neither the presence of the glycoprotein nor its interaction with the capsid is 
a prerequisite for virus release, although they might enhance particle release. 
2. Immature capsids with encapsidated RNA genome assemble first in the cytoplasm. Then they travel 
to the budding site, in some cases assisted by the viral glycoprotein. The budding site can be either 
plasma membrane or an intracellular compartment (such as endoplasmic reticulum (ER) or Golgi), 
where the envelope protein is localized. This mechanism characterizes B/D-type retroviruses such 
as Mason-Pfizer monkey virus (MPMV) and mouse mammary tumor virus (MMTV) [5–7]. 
Interestingly, outside the retrovirus family, budding of Hepatitis B virus (HBV), a member of the 
reverse transcribing Hepadnaviridae family, shares some similarities with the B/D-type retroviruses, in 
that HBV cores assemble in the cytoplasm prior to being enveloped and released from the cell [8,9].  
A major difference of HBV to orthoretroviruses is that the nucleocapsids contain viral DNA reverse 
transcribed from packaged viral pre-genomic RNA, which is a prerequisite for subsequent HBV core 
envelopment at the pre-Golgi compartment. The HBV virions bud through this cellular compartment 
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and are finally released from the cell by exocytosis. Unlike most retroviruses (e.g., HIV-1, MuLV), 
HBV virions depend on the presence of the envelope proteins for successful budding from the cell. 
Figure 1. Retroviral capsid assembly and budding strategies. Schematic illustration of the 
capsid assembly and budding strategies of C-type (human immunodeficiency virus type 1, 
HIV-1), B/D-type (Mason-Pfizer monkey virus, MPMV), and foamy viruses (prototype 
foamy virus, PFV).  
 
2. Foamy Virus Budding, an Overview 
Some years ago, retroviruses were reclassified into two separate subfamilies with spuma- or foamy 
viruses (FVs) as the only genus of the Spumaretrovirinae subfamily [10]. The realization that the FV 
replication strategy represents a link between Retro- and Hepadnaviridae is among the reasons leading 
to this reclassification and make FVs to interesting research subjects [11]. The FV budding strategy 
certainly strengthens this notion, as it combines steps that occur during budding of some retroviruses, 
with unique characteristics common to HBV. In this review, which summarizes the current knowledge 
on FV budding, most aspects are described for Prototype FV (PFV), originally known as human FV 
(HFV), the best studied FV species. However, if information is available for other FV species or there 
are known mechanistic differences between individual FV species, this will be addressed accordingly. 
Important features of the budding strategy of FVs in comparison to hepadnaviruses and 
orthoretroviruses are summarized in Table 1.  
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Table 1. Features of HIV-1, RSV, PFV and HBV budding strategies.  
Virus species 
Retroviroviridae Hepadnaviridae 
Human Immunodeficiency Virus 
Type 1 (HIV-1) 
Rous Sarcoma Virus (RSV) 
Prototype Foamy Virus 
(PFV) 
Hepatitis B virus (HBV) 
Glycoprotein 
organization 
Polyprotein precursor (gp160):  
Surface glycoprotein (gp120
SU
) 
Transmembrane glycoprotein 
(gp41
TM
) 
Polyprotein precursor (gp95): 
Surface glycoprotein (gp85
SU
) 
Transmembrane glycoprotein 
(gp37
TM
) 
Polyprotein precursor (gp130): 
Surface glycoprotein (gp80
 SU
)  
Transmembrane glycoprotein 
(gp48
 TM
) 
Leader peptide (gp18
LP
) 
Hepatitis B surface antigen 
(HBsAg): 
Small (S) protein (226aa) 
Middle (M) protein (226aa + 
preS2 domain 55aa) 
Large (L) protein (226aa + preS2 
domain 55aa + preS1 domain 
108aa or 119aa) 
Capsid 
organization 
Gag precursor (Pr55
Gag
): 
Matrix (p17
MA
); 
Capsid (p24
CA
); 
Spacer p2 
Nucleocapsid (p7
NC
); 
Spacer p1; 
p6 domain 
Gag-PR precursor (Pr76
Gag-PR
): 
Matrix (p17
MA
); 
p2a, p2b; 
pp10; 
Capsid (p27
CA
); 
Spacer; 
Nucleocapsid (p12
NC
); 
Protease (p15
PR
) 
Gag precursor (p71
Gag
): 
 
p68
Gag
; p3
Gag
 
 
Hepatitis B core protein (p22
HBc
): 
183-185aa  
 
Capsid: membrane 
targeting domain 
Present in MA subunit Present in MA subunit No Not known 
Budding type 
Type C morphogenesis:  
Assembly takes place 
at the plasma membrane;  
particle release from plasma 
membrane or plasma membrane-
derived membranes 
Type C morphogenesis: 
Assembly takes place 
at the plasma membrane;  
particle release from plasma 
membrane or plasma membrane-
derived membranes 
Type B/D morphogenesis: 
Capsid preassembly at the  
MTOC in the cytoplasm; 
budding from intracellular 
membranes (ER/Golgi) and 
plasma membrane 
Nucleocapsid-formation in 
cytosol;  
Budding from intracellular 
membranes (ER) 
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Table 1. Cont. 
Virus species 
Retroviroviridae Hepadnaviridae 
Human Immunodeficiency 
Virus Type 1 (HIV-1) 
Rous Sarcoma Virus (RSV) Prototype Foamy Virus (PFV) Hepatitis B virus (HBV) 
ESCRT-dependent 
budding process  
Yes 
ESCRT I, III 
AIP1/Alix 
Vps4A/B 
Yes 
ESCRT II, III 
AIP1/Alix 
Vps4A/B 
Yes 
ESCRT I, III 
Vps4A/B 
Yes 
ESCRT II, III 
Vps4A/B 
L domain 
Gag (p6):  
PTAP; YPXL 
Gag (p2b):  
PPPY; LYPSL 
Gag (p71, p68):  
PSAP 
Core:  
PPAY; K96? 
ESCRT interaction 
partner 
Tsg101; AIP1/Alix;  AIP1/Alix; (Nedd4) Tsg101 (Nedd4); (2-adaptin) 
Virus like particles Yes Yes No No, but release of naked capsids  
Subviral particles No No Yes, low amounts Yes, high amounts 
Budding requires 
Capsid (Gag) protein only Capsid (Gag) protein only Capsid (Gag) and Envelope 
protein (Env) necessary 
Capsid (Core) and Envelope protein (L 
and S) necessary 
vDNA synthesis 
Place of interaction 
(Capsid-Envelope) 
plasma membrane  plasma membrane  trans-Golgi network ER 
Pseudotyping yes yes 
yes, but only with a artificial 
heterodimerizer system 
no 
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3. Glycoprotein-Dependent Particle Release  
Unlike orthoretroviruses, but analogous to hepadnaviruses, a hallmark of FV egress and 
transmission to new host cells is the strict requirement of a very specific interplay between capsids and 
the cognate glycoprotein [12–14]. Association of FV capsids with or budding across membranes in the 
absence of Env coexpression is not observed [12–15]. Apparently, FV Gag proteins lack membrane-
targeting domains (MTDs) that are inherent to orthoretroviral capsid proteins and enable VLP release. 
Not alone is Env co-expression important to direct Gag to cellular membranes, but also the presence of 
Gag is necessary for efficient transport of Env to the cell surface [16]. Furthermore, heterologous viral 
surface proteins fail to substitute the essential FV Env function in particle morphogenesis. These 
notions support the idea of a very specific and potential direct interaction of Gag and Env protein 
essential to the FV budding process [12–14]. Nevertheless, what are the underlying molecular 
mechanisms and details of this exceptional retroviral budding strategy? Some of the unique features of 
the FV egress strategy are based on the unusual biosynthesis and special characteristics of the FV 
structural proteins.  
3.1. FV Capsid- and Glycoprotein Biosynthesis 
FV capsid protein biosynthesis. Like most of the viral structural proteins, FV Gag is expressed on 
free ribosomes in the cytoplasm. The subdomain structure and maturation of FV Gag proteins is quite 
different to other retroviral capsid proteins (see Müllers and Lee et al. in this issue for further details) 
(Figure 2A). In contrast to orthoretroviruses, only one primary protease cleavage site in the FV Gag 
precursor is utilized by the viral protease during assembly [17]. For PFV the 71 kDa Gag precursor is 
processed into a large p68
Gag
 subunit and a small p3
Gag
 protein. Both the Gag precursor and the large 
cleavage product are found in released FV particles at ratios of 1:1 to 1:4 [18–21]. Due to its small size 
the p3
Gag
 evaded so far detection by immunoblotting or immunoprecipitation techniques [22]. 
Therefore, it remains unclear whether p3
Gag
 constitutes a stable product of FV Gag precursor 
processing and may be a structural component of infectious viral particles.  
FV glycoprotein biosynthesis. The biosynthesis of the FV Env protein is unique in comparison to 
the other retroviral glycoproteins. The full-length FV Env precursor protein is translated at ribosomes 
of the endoplasmatic reticulum (ER) membrane and is inserted into membrane with N- and C-termini 
located in cytoplasm (Figure 3) [15,24,25]. FV glycoprotein precursor processing by cellular proteases 
displays analogies and differences to orthoretroviruses. Like in orthoretroviruses the central surface 
(SU) and C-terminal transmembrane (TM) subunits of FV are derived from the glycoprotein precursor 
by furin or furin like protease-mediated processing, probably occurring in late compartments of the 
Golgi (Figure 3A) [26,27]. All known FV Env proteins harbor consensus motifs of optimal furin 
cleavage sites (RX[K/R]R) between both subunits. SU/TM processing does not significantly influence 
particle egress but is essential for infectivity of released FV virions [16,28,29]. Similar to HIV Env, 
but different to other orthoretroviruses, FV Env proteins are not cotranslationally processed by the 
signal peptidase [15,24,30]. However, whereas HIV-1 Env is posttranslationally cleaved by signal 
peptidase, additional processing by furin or furin-like proteases was discovered for PFV Env or FFV 
proteins [26,27,30]. All known FV species contain one or multiple minimal (RxxR) or optimal furin 
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cleavage site consensus motifs between N-terminal leader peptide (LP) and central SU subunit [26–28]. 
Unlike processing of the SU- and TM subunits separation of LP- and SU subunits is not essential to 
virion infectivity but has some influence on the efficiency of particle release [26,27]. A processing of 
the viral glycoprotein by the viral protease, as reported for some orthoretroviruses, has not been 
detected during the transport of the FV Env precursor through the secretory pathway to the plasma 
membrane ([31,32] and unpublished observations). 
Figure 2. Foamy virus Gag. (A) Schematic organization of PFV Gag protein. The primary 
cleavage site within the p71
Gag
 precursor resulting in processing into p68
Gag
 and p3
Gag
 
cleavage products is indicated by an arrow. CC1-4: putative coiled-coil motifs; CTRS: 
cytoplasmic targeting and retention signal; L: late assembly domain (PSAP); A: assembly 
domain (LYxxLGL); GR-I-III: glycine-arginine rich boxes I to III. Numbers indicate 
amino acid position in PFV Gag; (B) Sequence alignment of putative L-domain motifs of 
different FV species. Consensus L-domain motifs are shown in red on top. FV sequences 
matching the L-domain motif consensus are marked in dashed, blue boxes. Sequences used 
for alignment were retrieved from GenBank. PFV: prototype foamy virus, human foamy 
virus Y07725.1; SFVcpz: chimpanzee simian foamy virus, NC001364.1; SFVgor: gorilla 
simian foamy virus, HM245790.1; SFVora: orangutan simian foamy virus, AJ544579.1; 
SFVmac: macaques simian foamy virus, NC010819.1; SFVagm: African green monkey 
simian foamy virus, NC010820.1; SFVmar: common marmoset simian foamy virus, 
GU356395.1; SFVspm: spider monkey foamy virus, EU010385.1; SFVsqu: squirrel 
monkey foamy virus, GU356394.1; FFV: feline foamy virus, Y08851.1; BFV: bovine foamy 
virus, NC001831.1; EFV: equine foamy virus, NC_002201.1; SloEFV: sloth endogenous 
foamy virus, [23]. Complete Gag sequences were aligned using MacVector software and 
Gonnet matrix and sequence surrounding putative FPxV or PPxY L-domain motifs 
extracted. For PSAP L-domain motifs the core consensus motif together with four N- and 
C-terminal flanking amino acids extracted and manually aligned. Sequence identities are 
shaded in grey. Numbers indicate amino acid position in the respective full-length protein. 
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Figure 3. Foamy virus Env. (A) Schematic organization of PFV Env protein. The furin 
cleavage sites within the gp130
Env
 precursor that are used for generation of the mature 
gp18
LP
, gp80
SU
, and gp48
TM
 subunits are indicated by grey arrows. The individual subunits 
are shown as boxes in different shades of green. Hydrophobic sequences spanning the 
membrane in LP (h) and TM (MSD) subunit are indicated. Enlarged are the N-terminal 
cytoplasmic domain (CyD) of the LP subunit and the C-terminal CyD of the TM subunit 
with sequence alignment of different FV species. Domains reported to be essential for SVP 
release are marked by solid green bars and domains inhibiting SVP release are marked by 
solid red bars on top of the enlargements. Complete Env sequences of different FV species 
were aligned using MacVector software and Gonnet matrix. Sequence identities are shaded 
in grey. For the TM CyD sequences additional manual alignments were introduced to 
better illustrate the location of the ER retrieval signal (KKK), marked by dashed, blue 
boxes. The evolutionary conserved WxxW motif in the CyD of the LP subunit, important 
for the interaction with the capsid, is marked with a dashed, blue box. The lysine residues 
in PFV Env LP that were experimentally confirmed to be ubiquitinated are highlighted in 
red. Sequences used for alignment were retrieved from GenBank. PFV: prototype foamy 
virus, human foamy virus Y07725.1; SFVcpz: chimpanzee simian foamy virus, 
NC001364.1; SFVgor: gorilla simian foamy virus, HM245790.1; SFVora: orangutan 
simian foamy virus, AJ544579.1; SFVmac: macaques simian foamy virus, NC010819.1; 
SFVagm: African green monkey simian foamy virus, NC010820.1; SFVmar: common 
marmoset simian foamy virus, GU356395.1; SFVspm: spider monkey foamy virus, 
EU010385.1; SFVsqu: squirrel monkey foamy virus, GU356394.1; FFV: feline foamy 
virus, Y08851.1; BFV: bovine foamy virus, NC001831.1; EFV: equine foamy virus, 
NC_002201.1; SloEFV: sloth endogenous foamy virus, [23]. (B) Membrane topology of 
the PFV Env precursor gp130
Env
. N-terminus (NH2) and C-terminus (COOH) are 
indicated. Attached ubiquitin molecules (Ub) are indicated as red balls. 
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During insertion in the secretory pathway and transport to the cell surface FV glycoproteins are 
heavily N-glycosylated [33]. For PFV a detailed mutagenesis analysis characterized posttranslational 
modification at 14 out of 15 potential N-glycosylation sites, some of which are evolutionary conserved 
amongst different FV species (Figure 3) [28,33]. The differential sensitivity to specific glycosidases 
indicated that all oligosaccharides on LP and TM are of the high-mannose or hybrid type, whereas 
most of those attached to SU, which contribute to about 50% of its molecular weight, are of the 
complex type [33]. Notably, individual inactivation of all PFV N-glycosylation sites revealed defects 
in intracellular processing, support of particle release, and infectivity only for three evolutionary 
conserved N-glycosylation sites [33]. Whether FV glycoproteins contain O-linked carbohydrates as 
reported for some orthoretroviral Env proteins is currently unknown [34,35]. 
For PFV the unusual biogenesis of the glycoprotein yields in particle-associated glycoprotein 
complexes consisting of a LP- (gp18
LP
) and TM subunit (gp48
TM
) with type II and type I membrane 
topologies, respectively, as well a luminal SU subunit (gp80
SU
), which probably is covalently 
connected by disulfide bridges to the TM subunit [15]. Very recently, it was reported that the PFV LP 
subunit is a substrate for cellular signal peptide peptidases, resulting in a processing in the hydrophobic 
membrane-spanning domain and indeed smaller LP cleavage products can be detected in lysates of FV 
infected cells and released particles [15,24,36]. The very recently reported additional processing of the 
FV glycoprotein leader peptide by signal peptide peptidase might reveal such an unexpected function. 
The situation is reminiscent to MMTV where the signal peptide targeting the glycoprotein to the 
secretory pathway is reported to function as a Rev-like RNA export factor, after being processed by 
signal peptidase and released into the cytoplasm [37,38]. To date such a factor has not been identified 
for FVs. It is therefore tempting to speculate that the FV Env LP cleavage product may possess similar 
functions in the viral RNA export as the signal peptide of the MMTV Rem and Env proteins. 
3.2. Subcellular Localization of FV Budding 
FV egress shows many features of orthoretroviruses following a B/D type assembly strategy (Figure 1). 
This includes assembly of capsids, consisting of FV Gag protein and viral genomic RNA (vgRNA), at 
a pericentriolar region, which was demonstrated to represent the centrosome or microtubule organizing 
center [39]. Similar to MPMV, FV Gag is targeted to the centrosome via a cytoplasmic targeting and 
retention signal (CTRS) found in the capsid protein (Figure 3) [6,40]. Transport of Gag or Gag-RNA 
complexes to the centrosome is dependent on microtubules of the host cell [39]. 
FV budding is reported to occur at different cellular membranes/locations [12,19,41]. All known 
FV species with one exception are thought to bud predominantly into intracellular compartments, a 
phenotype that correlates with an ER retrieval signal located at the C-terminus of the respective 
glycoproteins (Figure 3) [28,42,43]. Electron microscopy analysis of equine FV (EFV) infected cells 
suggests that it is the only FV species known to date that buds exclusively at the plasma membrane, 
which is explained by the lack of a C-terminal ER retrieval motif in EFV Env [28,41]. However, 
budding at the cell surface is also observed for other FV species, although at a much lower level as 
seen into apparently intracellular vacuolar structures [12,44]. However, the nature of these intracellular 
vacuolar budding compartment is poorly defined. Initial reports suggested them to represent  
ER-derived compartments, in line with a retrieval signal-mediated retention of the FV glycoprotein in 
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the ER [12,44]. To date only for PFV the subcellular localization of the intracellular budding site was 
investigated in greater detail in infected Hela cells, by immunostaining of viral structural proteins and 
colocalization analysis with organelle specific markers [39]. The results suggest PFV budding to take 
place at membranes of the trans-Golgi network (TGN). PFV Gag and Env localized both with similar 
efficiency to TGN components and not to components of the pericentriolar region (unlike MPMV), the 
ER, late endosomes or multivesicular body (MVB). How FV particles budding into intracellular 
compartments transit to the cell surface is currently unclear, since no virion-containing vesicles fusing 
with the plasma membrane were observed in infected cells [12,39]. Only in cells expressing a specific 
PFV Env mutant, having the membrane-spanning-domain of the TM subunit replaced by MuLV and 
displaying a cell surface transport-deficient phenotype, vesicles containing single or few budded 
virions were observed [12]. Particle release into the supernatant of cells expressing this PFV Env 
mutant was not detectable, and budding structures were only observed at intracellular membranes but 
not at the cell surface. These virion-containing small vesicles might represent transport vesicles that 
are naturally employed after budding into intracellular compartments for rapid release, stuck in their 
transit to the cell surface. 
Notably, FV infections are highly cytopathic in vitro, leading to a strong cytoplasmic vacuolization 
of most host cells and pronounced syncytia formation, as a consequence of FV glycoprotein-mediated 
cell-cell fusion [16,39] Therefore, it has to be clarified whether this may lead to changes in the 
intracellular architecture and an altered localization of endogenous cellular organelle markers, thereby 
complicating the characterization the FV budding sites in studies using infected cells. Furthermore, the 
notion of predominant intracellular budding of most FVs deduced from multiple electron microscopy 
studies of FV expressing cells should also be taken with caution due FVs cytopathogenicity inducing 
cell morphology alterations. The putative intracellular budding sites of most FVs may represent plasma 
membrane invaginations, similar to budding structures reported for HIV in infected macrophages [2,45]. 
Alternatively, FV particles found in intracellular vacuolar structures in electron micrographs may have 
been endocytosed after release at the membrane, as reported for HIV in certain cell types [46]. 
3.3. Details of FV Gag-Env Interaction 
The unusual biosynthesis of the FV glycoproteins already indicates that they have additional 
functions in the replication strategy of FVs, besides determining the virus tropism and facilitating 
target cell entry by interacting with host cell receptor molecules. The Env LP subunit is a physical 
constituent of the particle-associated glycoprotein complex, which suggests that it might be involved  
in particle morphogenesis in addition to targeting the glycoprotein precursor to the secretory  
pathway [15,25]. Indeed, it was experimentally confirmed for PFV and FFV that the Env LP subunit 
harbors the main determinants responsible for the glycoprotein-dependent egress of FV virions. In 
particular, the N-terminus of the cytoplasmic domain of LP, containing an evolutionary conserved 
WxxW motif, is essential for a specific interaction with the capsid protein during the budding process 
(Figure 4) [15,25]. Biophysical and co-precipitation approaches using recombinant Gag and Env 
domains or peptides suggest a direct interaction between the Env LP subunit and the capsid protein, 
that appears to be sufficient for promoting particle release [24,25,47]. However, the N-terminal region 
of the hydrophobic membrane-spanning domain of the PFV Env TM subunit was also reported to 
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influence the Gag-Env interaction [12]. However, it is currently unclear whether modifications in this 
part of Env abolish particle egress by direct inactivation of an interaction-domain with Gag. Instead, 
alternative membrane anchorage of the PFV Env may induce changes in the glycoprotein that 
indirectly prevent the LP domain-mediated physical interaction with Gag either by inducing global 
structural changes or altering intracellular trafficking or distribution of Env [12,48]. 
Figure 4. The specific foamy virus capsid – glycoprotein interaction essential for viral 
budding. Schematic illustration of FV precursor processing after insertion into the 
secretory pathway and interaction with the viral capsid (in red) essential for budding of 
virions. The order of LP/SU (solid arrow) and SU/TM (striped arrow) processing resulting 
in the different Env subunits (indicated in different shades of green) has not been defined. 
N-terminus (NH2) and C-terminus (COOH) are indicated. The essential WxxW motif in 
the LP CyD is indicated by blue W characters. 
 
The determinants of FV Gag essential for the interaction with the cognate Env protein are only 
poorly defined [18,24,25,49–52]. Previous studies suggest that they reside in the N-terminal part of the 
Gag protein. It was demonstrated that the N-terminal 297 aa of PFV Gag, containing the essential L 
domain, are sufficient for an efficient Gag release into the supernatant when coexpressed with PFV 
Env [18,52]. Furthermore, small deletions within the N-terminal part of the protein abolished capsid 
egress and N-terminal fusion of protein tags to PFV Gag appear to interfere with viral egress in tag 
size dependent manner [18,50,51]. In addition, surface plasmon resonance studies using recombinant 
N-terminal protein fragments of FFV Gag (corresponding to PFV Gag aa1-180) and FFV Env peptides 
or recombinant protein fragments (corresponding to PFV Env aa1-28 or aa1-61) suggest a direct low 
affinity interaction between both proteins [24,25]. Finally, recent experiments from our lab employing 
recombinant protein fragments and co-precipitation assays confirm a direct interaction between PFV 
Gag and PFV Env and suggest an essential role of a putative N-terminal coiled-coil domain in PFV 
Gag for the WxxW-motif-dependent binding to PFV Env LP subunit (Figure 2) [47]. 
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4. Cellular Factors Involved in FV Budding  
In numerous cases, the budding of enveloped viruses from the cells is influenced by or requires 
cellular factors [1,53]. For pericentriolar assembly of capsids and budding of virions at different 
cellular membranes in an FV infected cell, FV structural proteins and preassembled capsids must 
traffic along different pathways within the host cell. Like other viruses, these steps in viral replication 
are aided by certain cellular components, but inhibited also by some others. However, unlike other 
retroviruses such as HIV-1, few cellular factors are presently known that promote FV egress from 
infected cells or act as restriction factors in these processes. 
One cellular factor known to interfere with FV particle egress to date is tetherin [54,55]. Tetherin is 
an interferon 1-inducible transmembrane protein originally identified to inhibit HIV-1 release by 
tethering virions to the cell surface [56,57]. Later, it was demonstrated that tetherin has a broad 
antiviral activity inhibiting the release of various kinds of retroviruses, including FVs, and other 
viruses such as filoviruses [1]. 
Unlike inhibitory factors, several cellular factors or machineries promoting or being essential for 
FV release have been identified so far. For example, the cytoskeleton of the host cells is an important 
structure for viral protein trafficking and particle release, as observed for other retroviruses. Incubation 
of infected cells with microtubule-depolimerizing drugs such as nocodozale or colchicine strongly 
interferes with trafficking of FV Gag to and capsid assembly at the centrosome, as well as particle 
release [39,58,59]. PFV Gag is reported to interact with a light chain of dynein motor proteins through 
a conserved putative coiled-coil domain in N-terminal part of the protein during virus entry [58]. This 
suggests the use of these motor proteins for intracellular trafficking of the Gag protein and capsids. 
Notably, inactivation of this Gag motif also prevents centrosomal localization of de novo synthesized 
Gag upon transfection of cells. Whether the same motors are indeed utilized for assembly and/or 
egress as well has not been investigated in further detail.  
Similar to other retroviruses FVs were also found to hijack proteins of the vacuolar protein sorting 
(Vps) machinery for the budding and fission steps of virion egress [52,60–62]. Finally, the cellular 
ubiquitination machinery, also implicated in participating in cellular cargo protein sorting, interacts with 
FV virions during egress, resulting in posttranslational modification of FV structural proteins [63,64]. 
Our knowledge on the interaction of FVs with both types of cellular machineries is summarized in the 
next paragraphs. 
4.1. The ESCRT Machinery 
For all retroviruses, including foamy viruses, a set of proteins belonging to endosomal sorting complex 
required for transport (ESCRT) machinery is involved in particle egress. The ESCRT components are 
naturally utilized by the cell for sorting of cargo into multivesicular bodies (MVBs), a process that 
involves trafficking of proteins through various intracellular compartments [65]. Components of 
ESCRT take part in enabling cargo-enriched vesicles to bud into the lumen of MVBs and mediate the 
scission events that lead to final release of vesicles into MVB space, which is topologically 
reminiscent to virus budding. Also, this machinery is involved in final steps of cell division and 
specializes in mediating membrane scission events. As obligatory parasites, enveloped viruses have 
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found a way to hijack the system by directing some of its components to enable budding of virions 
from the cells [2,66]. 
Retroviruses are able to recruit ESCRT components during budding via interactions mediated by their 
capsid precursor protein. Each retroviral Gag contains, at different locations throughout the protein, one 
or more of specific motifs named “late assembly” or L domains due to their central role in promoting late 
events in intracellular virus life cycle. Until present, three major L-domain sequences essential for 
position-independent ESCRT complex recruitment have been identified [67,68]. P(T/S)AP motifs 
initially characterized in HIV-1 Gag, but also present in other retroviral capsid precursors, enable 
budding on account of interaction with Tsg101, a component of the ESCRT I complex. (L)YPxnL 
motifs, the best characterized one found in equine infectious anemia virus (EIAV) and HIV-1 Gag 
proteins, utilize interactions with AIP-1/ALIX to recruit ESCRT III complex components for budding. 
PPxY motifs found in MuLV, HTLV-1 and avian sarcoma/leukosis virus (ASLV) capsid precursors or 
the HBV core protein promote budding by binding to the WW domains of a subset of NEDD4-like 
HECT ubiquitin ligases. However, the mechanism of ESCRT III component recruitment by these 
motifs remains elusive. Multiple, possibly redundant pathways for linking HECT ubiquitin ligases with 
the core ESCRT machinery are discussed. A fourth motif, FPIV (consensus ØPxV;_in which Ø is any 
aromatic amino acid) found in the M protein of paramyxovirus simian virus 5 was reported to have L 
domain activity and complement the budding defect of L-domain deficient HIV-1 Gag [69]. However, 
its cellular interaction partner is unknown and other viruses using a FPIV L domain motif have not 
been identified to date. Notably, many retroviral Gag proteins contain more than one type of L-domain 
motif and therefore can presumably use alternative pathways of intracellular trafficking involved in the 
budding process [1,70]. Furthermore, different requirements of particular retroviruses for individual 
ESCRT complexes are known, e.g., HIV utilizes ESCRT-I but not ESCRT-II while ASLV utilizes 
ESCRT-II but not ESCRT-I complexes. Markedly, regardless of the individual ESCRT component 
hijacked by the different retroviruses, all the budding strategies involve a common requirement. This is 
the dependence on ESCRT-III complex and catalytically-active ATPase Vps4, which enables final 
pinching off of a virus particle and recycling of ESCRT components recruited [1,68]. 
In case of FVs, motifs with perfect or some homology to the three major L domains were initially 
identified in the PFV Gag protein [52,62]. However, only the PSAP motif has been shown by 
mutagenesis analysis to act as a “true” late domain and to mediate efficient PFV budding via 
interaction with Tsg101. For the other two motifs, a YEIL and a PPPI motif, the suspected L domain 
function could not be confirmed. Later on a function as an interaction-domain influencing capsid 
morphology was reported for the YEIL motif, in context of a conserved (Y/F)xxLGL consensus motif 
present in all FV species [71]. The PPPI motif has no clear function attributed yet, although its 
mutation severely reduces viral infectivity without affecting particle release [52,62]. Another evidence 
supporting the notion that PFV particle budding is dependent on ESCRT pathway is the absolute 
requirement of the functional Vps4 protein. Overexpression of a dominant negative form of this 
ATPase in virus-producing cells led to a complete inhibition of release of particles with a functional 
PSAP motif [52,62]. 
Notably, all experimental data on the ESCRT recruitment by FVs has been obtained only for PFV. 
All primate FVs contain one to three P(S/T)AP L domain motifs (Figure 2B). Whereas these motifs are 
located in a central region of most primate FVs, spider monkey FV (SFVspm) Gag harbors an 
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additional motif in the C-terminal p3
Gag
 subunit and the single PSAP motif of orangutan Gag is placed 
at the C-terminus of the p68
Gag
 subunit (Figure 2B). Interestingly, all non-primate FV species lack 
P(S/T)AP L domain motifs. Although unlikely, this raises the possibility that budding of these FVs is 
ESCRT-independent as reported for some other viruses [68]. Alternatively, and more likely, the capsid 
precursor proteins of non-primate FVs species may harbor yet uncharacterized L domain motifs. 
Notably, an additional PPRY motif that matches the PPxY L-domain consensus motif is found in the 
C-terminal part of squirrel monkey FV (SFVsqu) Gag. This motif fits a (Q/R)P(Q/A/S/P)R(Y/L)G 
consensus motif located at this position in all FV species (Figure 2B). Furthermore, all FFV Gag 
sequences contain FPIV and FPRV peptides that are perfect matches of the ØPxV L-domain consensus 
motif of the paramyxovirus simian virus 5 M protein (Figure 2B). 
4.2. The Ubiquitination Machinery 
The cellular ubiquitination machinery is implicated to be involved in the release of different viruses, 
in particular those hijacking the ESCRT machinery [72–75]. This notion derives from the observation 
that monoubiquitination of cargo serves as a signal for recognition and trafficking mediated by the 
ESCRT machinery [76]. Furthermore, free ubiquitin and ubiquitinated Gag proteins were detected in 
various kinds of retroviral particles in an L-domain dependent manner [72,73]. Finally, late budding 
defects induced by proteasomal inhibitor treatment or L-domain deletion can be alleviated by direct 
fusion of ubiquitin to the C-terminus of Gag proteins [60,77]. However, whether direct ubiquitination 
of retroviral capsids or of cellular proteins are critical for ubiquitin-dependent viral particle release 
remains unclear. 
In the course of characterizing the budding pathways of different PFV particle structures 
ubiquitinated glycoprotein subunits were readily observed in lysates of released PFV particles (see 
below) [63]. The lack of Gag ubiquitination noted in these studies was not surprising since most FV 
Gag proteins have the unusual feature that they are completely or almost devoid of lysine residues, the 
acceptor sites of ubiquitination [60,63,78]. Strikingly, FFV Gag is special in this respect among FV 
capsid precursors since it contains the largest number of lysine residues and has five out of eight 
lysines clustered in the p3
Gag
 domain. Zhadina et al. [61] took advantage of this observation and the 
paucity of lysine residues in PFV Gag to determine whether retroviral capsid precursor protein 
ubiquitination is generally required for enveloped virion release. They used an artificial virus VLP 
system comprising an Env-independent budding PFV Gag protein with attached N-terminal 
heterologous membrane-targeting domain and conservatively mutated the single lysine residue in the 
PFV capsid precursor [61]. With a mutant variant of this PFV Gag protein, having the natural PSAP  
L-domain motif replaced by a heterologous PPxY motif, they could demonstrate that for the PPxY  
L-domain motif and ubiquitin ligase activity dependent particle release, ubiquitination of Gag was 
dispensable. Thus, ubiquitination of transacting factor rather than viral proteins appears critical for 
ubiquitin-dependent enveloped particle release. In a follow-up study, they reported a flexibility in the 
ways in which the ESCRT machinery can be recruited and how ubiquitin can be co-opted to enable 
this, for example attachment to Gag or involved cellular proteins [60]. These results indicate that our 
current view on cellular components involved in retrovirus budding should be expanded, as the routes 
of host factor hijacking by viruses are probably more intricate than already identified.  
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Notably, viruses in general and also retroviruses in particular utilize the cellular ubiquitination 
machinery for replication also in another way, namely for neutralization of cellular antiviral  
factors [1,79,80]. By different mechanisms, they induce attachment of polyubiquitin chains to these 
factors thereby driving them into proteasomal degradation. Examples for this are the proteasomal 
degradation of tetherin mediated by HIV-1 Vpu or the HIV-1 Vif induced inactivation of APOBEC3 
proteins, which is encapsidated in retroviral virions and edits the viral genome during reverse 
transcription. Both cellular factors are also known to interfere with FV replication [54,55,81–83]. 
However, a defense mechanism of FVs against tetherin restriction has not been identified [54,55]. 
Furthermore, ABOBEC3 proteins are neutralized by the FV accessory protein Bet through binding and 
sequestration rather than routing the cellular proteins to proteasomal degradation [84,85]. 
5. Alternative and Artificial Budding of FV Particle Structures 
5.1. Subviral Particles 
As previously mentioned, FV replication cycle is highly related to orthoretroviruses, but some 
aspects are more similar to hepadnaviruses. For instance, hepadnaviral infection is characterized by 
massive overproduction of subviral particles (SVP) [8,9]. These are released empty vesicles that 
contain only viral glycoproteins but no viral capsids or genomes and are non-infectious. Hepatitis 
envelope protein (HBsAg) alone is sufficient for mobilization of cellular lipids, self-assembly, 
intracellular transport and secretion [86]. Budding of subviral particle occurs from intracellular, post-ER 
pre-Golgi membranes [87,88]. SVP of HBV reach a 1,000–100,000-fold higher concentration in serum 
than infectious Dane particles, which represents an advantage of the virus against the host’s immune 
system [89,90]. SVP might neutralize antibodies produced from the immune system to stem virus 
proliferation or lead to immune tolerance that allow persistent infection [90,91]. 
In 2003, subviral particles were first described for PFV [92] and FV Env expression was shown to 
be sufficient to induce SVP release (Figure 1). In contrast to hepadnaviruses only small amount of SVP 
in comparison to infectious particles are released. However, only limited knowledge about regulation 
strategies for subviral particles formation is available. Studies with PFV Env defined structural 
requirements for SVP release involving two essential and two inhibitory regions in the PFV Env LP 
and TM subunits (Figure 3A) [52]. In addition, ubiquitination of the glycoprotein at the N-terminal 
cytoplasmic domain (CyD) of its LP subunit was shown to regulate the level of SVP formation [63,64] 
(Figure 3). For PFV about one third of the particle-associated LP subunits were ubiquitinated at one or 
more lysine residues, detectable as LP variants with higher molecular weight stained with ubiquitin or 
LP-specific antibodies in Western blots of PFV particle lysates [63]. Inactivation of the first three or of 
all five potential ubiquitin attachment sites in PFV LP massively increased the release of SVP [63]. By 
contrast ubiquitination at the first or second, but not the other lysine residues of the LP CyD were 
alone sufficient to suppress PFV SVP [64]. Strikingly, LP subunit ubiquitination was detectable for 
PFV and SFVmac, but not for FFV Env [15,25,63]. 
Not only the cellular ubiquitination machinery is involved in egress of PFV SVPs. Unlike HBV 
SVP release, late components of the VPS machinery are also important for PFV SVP budding [64].  
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What potential functions SVP particles might have in natural FV infections is currently not known. 
Due to the low level of PFV SVP release observed, it seems unlikely that they serve as decoys for the 
immune system like HBV SVPs. It is possible that the low level PFV SVP release is only a byproduct 
of the unique glycoprotein-dependent egress strategy of infectious FV particles. They might be a 
consequence of intrinsic structural features of the FV glycoproteins for particle morphogenesis that are 
absent from orthoretroviral glycoproteins. 
5.2. Glycoprotein-Independent Capsid Membrane Targeting 
Unlike their orthoretroviral relatives, FVs normally depend on Gag-Env interaction for final release of 
particles from infected cells, because FV Gag lacks an authentic membrane-targeting signal [12–14]. 
However, artificial ways allowing release of VLPs without envelope being present have been 
developed for FVs. These systems, describing FV particulate structure release, have all utilized the 
same valuable observation by Pellman et al., that attaching a heterologous myristoylation signal  
from Rous Sarcoma virus Src protein to various cellular proteins can retarget them to plasma 
membrane [93]. Rous sarcoma virus membrane targeting and –binding domain (MTD) is responsible 
for directing Gag from cytoplasm to plasma membrane [94,95]. Hence, experimental systems using FV 
Gag proteins tagged with heterologous membrane-targeting signals have developed and demonstrated 
that FV budding from the cell can be induced in the absence of Env coexpression by providing these 
modified Gag proteins [40,49,51,61,96]. 
The ability of N-terminally myristoylated PFV Gag to form VLPs budding from the cell was first 
described by Eastman and Linial [40]. In this study, the PFV Gag CTRS was characterized by using 
proviral constructs having different point mutations in the Gag CTRS motif. Inactivation of the CTRS 
resulted in the abolishment of PFV budding and release and a nuclear accumulation of the mutant Gag 
proteins. By replacing the first ten N-terminal amino acids of these PFV Gag CTRS mutants with a 
heterologous MTD, the Src-myristoylation signal (v-src), the cellular distribution of Gag was altered 
leading to a plasma membrane localization of the Gag mutants. Furthermore, PFV budding was 
rescued at levels similar to or even higher than wild type and was no longer dependent on the 
coexpression of the cognate glycoprotein. However, these v-src-tagged viruses were non-infectious, 
independently of whether the FV glycoprotein was coexpressed or not. 
Further investigation of the particle morphogenesis of PFV Gag variants tagged with different 
plasma membrane localization signals showed, however, that the modifications did not alter the 
location of intracellular PFV capsid assembly in presence of an intact CTRS [51]. The presence of a 
functional FV Gag CTRS appears to dominantly target capsid assembly to the pericentriolar site in the 
cell. The non-infectious phenotype of the MTD-tagged virions correlated with aberrant capsid 
morphologies, most likely as a consequence of reduced Pol incorporation and decreased Gag processing.  
Other studies using additional membrane localization signals, such as fyn or lck myristoylation and 
palmitoylation motifs or the complete matrix (MA) domains of HIV-1 or MPMV Gag, confirmed  
Env-independent particle release capabilities of the tagged Gag proteins of PFV and FFV [49,61,96]. 
As originally reported by Eastman et al., several of the alternative MTDs display a severe interference 
with FV virion infectivity, capsid morphogenesis and Pol incorporation [40,96]. Notably, only 
targeting of FV Gag to the plasma membrane and not to endosomal membranes is compatible with 
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budding [96]. Another study with FFV Gag suggests that replacement of N-terminal FV Gag 
sequences by heterologous MTDs is less well tolerated than their N-terminal addition [49]. This is in 
line with a mutagenesis analysis of N-terminal MTD-tagged PFV Gag that demonstrated the 
interference of some MTD sequences with PFV morphogenesis when replacing the N-terminus of  
Gag [51]. However, a recent characterization of the Env interaction domain in PFV Gag indicates that 
the N-terminal 10 aa of PFV Gag are dispensable for Env-dependent morphogenesis and egress [47]. 
Taken together, these studies demonstrate that addition of heterologous plasma membrane targeting 
signals can compensate the lack of an endogenous MTD in FV Gag proteins and enable FV VLP 
release as inherent to orthoretrovirus Gag proteins. This also indicates that FV Gag harbors all other 
structural motifs necessary for capsid assembly and egress. Furthermore, the strong interference of 
permanent membrane association induced by MTD tagging of FV Gag proteins, due to their naturally 
limited proteolytic precursor processing features, strongly indicates that native FV virion 
morphogenesis includes only a transient membrane association, naturally mediated by the specific 
interaction with the cognate glycoprotein. 
5.3. Pseudotyping 
The term pseudotyping describes a phenomenon of viruses obtaining heterologous envelope 
proteins, a quite frequent occurrence upon infection of one cell with two different viruses. The primary 
consequence of such an event is broadening or narrowing of the natural virus host range, due to the 
features of the newly obtained envelope.  
Clearly, the ability to pseudotype different virus particles represent a valuable tool for development 
of viral vector systems, as the possibility of altering virus natural specificity opens vector applications 
to previously non-permissive cells and tissues [97,98]. Furthermore, pseudotyped viruses can have a 
safety advantage. For several retroviruses pseudotyping with heterologous Env proteins is reported [99]. 
For example, pseudotyping of lentiviral vectors with vesicular stomatitis virus glycoprotein (VSV-G) 
is the first used combination for pseudotyping lentiviruses. The resulted broad tropism and stability 
warrant the widely use of these vectors. 
Due to the specific interaction of FV Gag and Env proteins, which is a prerequisite for particle 
egress, FVs are naturally resistant to pseudotyping by heterologous glycoprotein, even from other 
retroviruses [12–14]. Only very recently, a system for pseudotyping PFV particles has been  
described [100]. The approach that finally enabled PFV particles to be pseudotyped is based on using a 
system, where the apparently transient interaction of FV Gag and FV Env is substituted by an 
inducible, small-molecule controlled heterodimerization (HD)-system. This system enabled 
pseudotyping of PFV particles by VSV-G for instance. More precisely, PFV capsid protein was fused 
to one HD domain (HDD), while another HDD was fused to a heterologous MTD, such as the HIV-1 
Gag MA subunit. Particles produced by coexpression of these components with the different envelope 
proteins, such as a naturally interaction-deficient PFV Env mutant or heterologous glycoproteins like 
VSV-G, displayed infectivity comparable to wild type PFV. Furthermore, PFV particles pseudotyped 
with heterologous glycoproteins were able to infect previously non-permissive PFV cell lines.  
Thus, successful pseudotyping of PFV capsids, opening new possibilities for FV vector design, has 
finally been achieved. 
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6. Conclusions 
The last ten to fifteen years of FV research has shown enormous progress in our understanding of 
how this type of retroviruses replicate within their host cells. The viral egress strategy these viruses 
have chosen in particular highlights their unique position among retroviruses. It demonstrates that they 
are at the interface between retroviruses and hepadnaviruses. In this review we summarized the current 
knowledge on the FV budding and release processes. In our opinion, many of the unique features 
characterized for these processes that deviate from the general orthoretroviral pathways are based on 
the unusual biosynthesis and special features inherent to the FV structural proteins. The strict 
requirement of an intimate interaction of the capsid and glycoprotein for membrane association and 
budding, as a consequence of a missing membrane targeting signal in FV Gag and the unusual 
posttranslational processing of the Env protein, is probably the best example for this. Although it is 
known that both proteins influence each other’s intracellular distribution and trafficking, the 
mechanisms regulating it and their interaction prior to budding and release is still poorly characterized. 
Another enigma that remains unsolved is how FV particles, for most FV species apparently budding 
predominantly at intracellular membranes, exit the host cell. Are these budding sites indeed 
intracellular compartments, or not? Is FV budding the rate-limiting step in egress, and are subsequent 
post budding steps so efficient and fast that we have not observed them until now in ultrastructural 
studies? Analysis of FV egress with fluorescently-tagged structural proteins by live-cell imaging in 
real-time that recently became available also for FVs might shed more light on this in the future. 
We are convinced that further examination of the biogenesis, trafficking and intracellular 
distribution of the FV Gag and Env but also the characterization of yet unknown cellular interaction 
partners will surface additional features and/or surprising functions of these proteins in the viral 
replication cycle. Enlarging our knowledge of the basic biology of these unusual retroviruses will also 
have an important impact in fostering their further development as gene transfer tools and potential 
applications in therapeutic strategies to cure various diseases. 
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